Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Manic Episode Clear all
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 7, 2026, 8:41 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Relapse & Recurrence of Bipolar Depression

NCT00961961
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium / Fluoxetine, Lithium / Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 2Phase 3 Interventional

BHV-7000 Acute Treatment of Bipolar Mania

NCT06419582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

NCT00277212
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lamotrigine + Aripiprazole, Lamotrigine + Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01396291
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
asenapine, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
Anaheim, California • Chino, California • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

NCT00596622
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium
Drug
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

NCT06462586
View directory record Official record
Conditions
Bipolar Disorder, Manic
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Bellflower, California • Culver City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 4 Interventional

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00139594
View directory record Official record
Conditions
Bipolar Disorder
Interventions
licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
La Palma, California • Kansas City, Kansas • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

NCT00228059
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 7, 2026, 8:41 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania
Interventions
KarXT, Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
52
States / cities
Glendale, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 7, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT06608641
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Drug
Lead sponsor
Jina Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Cerritos, California • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

NCT04819776
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Iloperidone, Iloperidone Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

NCT03573297
View directory record Official record
Conditions
Bipolar I Disorder, Mania, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920
View directory record Official record
Conditions
Bipolar Disorder With Manic or Mixed Episodes
Interventions
MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Sep 7, 2026, 8:41 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 7, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Little Rock, Arkansas • Cerritos, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 7, 2026, 8:41 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927
View directory record Official record
Conditions
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Dothan, Alabama • Downey, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 7, 2026, 8:41 PM EDT